Unaudited Interim Results to 30 June 2025
RNS Announcements
General Meeting Requisition Notice
25 September 2024
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to
support cardiometabolic health, announces that it has received a requisition notice
(“Notice”) dated 24 September 2024 from Platform Securities Nominees Limited, as the
legal holder of 8,643,583 ordinary shares of 0.05p each in the Company, held as
nominee on behalf of Seneca Partners.
The cumulative holding includes the interests of Seneca EIS (c/o WCS Nominees Ltd),
Seneca Growth Capital and the personal holdings of six individuals connected to
Seneca Partners and represents 5.46% of the Company's current issued share
capital.
The notice requests the Company's Board of Directors (the “Board”) to convene a
General Meeting (“Requisitioned GM”) under section 303 and 314 of the Companies Act
2006 (the “Act”).
A further announcement will be published within the next 21 days once the Board has
considered the Notice and the proposed resolutions. In the meantime, the Board
advises shareholders to take no action at this stage.
The Notice sets out three ordinary resolutions to be proposed at the Requisitioned
GM, which are set out below:
“Proposed Resolution 1: To remove Steen Andersen as a Director of the Company.
Proposed Resolution 2: To remove Frederik Bruhn-Petersen as a Director of the
Company.
Proposed Resolution 3: To remove any person appointed by the Board, after the date of this notice, as a Director of the Company.”
For further information, please contact:
ProBiotix Health plc | https://probiotixhealth-ir.com/ |
Steen Andersen, Chief Executive Officer | Contact via Walbrook below |
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) | |
Mark Anwyl |
Tel: 020 7220 9793 |
Walbrook PR Ltd | probiotix@walbrookpr.com |
Anna Dunphy | Mob: 07876 741 001 |
This information contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Aquis-listed ProBiotix Health
taps into demand for
cardiovascular disease treatments
Stephen O'Hara | 23
February 2023
IG UK | Youtube